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p = 0.059). Moreover, we found no DNA methylation in 
the TET2 and TET3 promoter regions in cancerous and his-
topathologically unchanged tissue. In contrast, we reported 
TET1 DNA hypermethylation in a small fraction of patients 
(n = 12/113).
Conclusion To best of our knowledge, our study is the 
first to investigate TET mRNA levels in a cohort of CRC 
patients and correlate them with patients’ prognosis. Pre-
sent study provides the evidence that TET2 mRNA expres-
sion may be an independent prognostic factor for disease 
recurrence and outcome. Additionally, our findings initially 
indicate the importance of DNA methylation in regulating 
TET1 expression.
Keywords DNA methylation · TET enzymes · Prognostic 
factor · Colorectal cancer
Introduction
Colorectal cancer (CRC) growth is influenced by genetic 
and epigenetic abnormalities. The most extensively charac-
terized epigenetic modification is methylation at the 5-car-
bon of cytosines, mostly in the context of CG dinucleo-
tides. Aberrant patterns of DNA methylation are observed 
from the early stages of CRC carcinogenesis (Dawson and 
Kouzarides 2012). DNA hypermethylation within promoter 
regions leads to the inactivation of CRC tumor suppressor 
genes, while hypomethylation is associated with genomic 
instability (Migliore et al. 2011). DNA methyltransferases 
(DNMTs), which establish and maintain DNA methylation 
patterns, are responsible for silencing tumor suppressor 
genes; thus, they are thought to be oncogenes (Linhart et al. 
2007). However, the role of the enzymes involved in DNA 
demethylation in CRC remains elusive.
Abstract 
Purpose Ten eleven translocation (TET) enzyme activ-
ity is essential for active DNA demethylation in biological 
processes, and their altered expression has been observed 
in various malignancies. Therefore, we investigated DNA 
methylation and mRNA levels of all TETs in colorectal 
cancer (CRC) patients.
Methods TET mRNA levels were evaluated using quan-
titative RT-PCR in primary cancerous and histopatho-
logically unchanged colorectal tissues from patients who 
underwent radical surgical colon resection (n = 113). DNA 
methylation levels of the TET CpG island were assessed 
using bisulfite DNA sequencing and high-resolution melt-
ing analysis.
Results We found reduced transcript levels of TET1, 
TET2 and TET3 in cancerous tissue compared with their 
histopathologically unchanged counterparts (p = 0.000011; 
p = 0.000001; p = 0.00031, respectively). Importantly, 
multivariate Cox regression analysis revealed favorable 
overall survival (OS) and disease-free survival (DFS) out-
comes for patients with high TET2 mRNA levels in histo-
pathologically unchanged tissue (HROS = 0.091, 95 % CI 
0.011–0.77, p = 0.028; HRDFS = 0.21, 95 % CI 0.04–1.06, 
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In 2009, two research groups identified independently 
ten eleven translocation 1 (TET1) activity to convert 
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine 
(5-hmC) (Ito et al. 2010; Tahiliani et al. 2009). Soon 
after, the TET2 and TET3 family members were charac-
terized (Ito et al. 2010). Moreover, studies revealed that 
the TET proteins further convert 5-hmC to 5-formylocy-
tosine (5-fC) and 5-carboxycytosine (5-caC) (He et al. 
2011; Ito et al. 2011). As a result, it has been suggested 
that the TET proteins participate in DNA demethylation 
processes through at least four mechanisms: replication-
dependent passive dilution of 5-hmC; removal of oxida-
tive cytosines by thymine-DNA glycosylase (TDG) and 
base excision repair system (BER); activation-induced 
deaminase/apolipoprotein B mRNA-editing enzyme 
complex (AID/APOBEC), which may deaminate 5-hmC 
to 5-hydroxyuracyl (5-hmU) that is then removed by 
TDG; and decarboxylation of 5-caC to an unmodified 
cytosine without BER activity (Guo et al. 2011; Hashi-
moto et al. 2012; Schiesser et al. 2012; Stivers and Jiang 
2003).
Recent studies have indicated lower level of 5-hmC 
and TET expression in many malignancies compared with 
normal tissues (Frycz et al. 2014; Lian et al. 2012; Liu 
et al. 2013; Muller et al. 2012). However, only one arti-
cle ascertained the expression of TET gene family mem-
bers in CRC in a small subset of patients (n = 22) (Kudo 
et al. 2012). Moreover, although the initial data indicates 
posttranscriptional and posttranslational control of TET 
expression, relatively little is known about their transcrip-
tional control (Delatte et al. 2014). Interestingly, all TET 
promoter regions contain CpG islands that can potentially 
undergo silencing by DNA methylation. Therefore, in this 
study, we investigated alterations in DNA methylation and 
mRNA levels of TET1, TET2 and TET3 in primary cancer-
ous and histopathologically unchanged colorectal tissues 
from a cohort of 113 patients. The results obtained were 




Primary colonic adenocarcinoma tissues were collected 
between June 2009 and March 2013 from a cohort of 113 
patients who underwent radical surgical resection of the 
colon at the Department of General and Colorectal Surgery, 
Poznan´ University of Medical Sciences, Poland (Table 1). 
Histopathologically unchanged colonic mucosa located 
at least 10–20 cm away from the cancerous lesions were 
obtained from the same patients. One set of samples was 
immediately snap-frozen in liquid nitrogen and stored 
at −80 °C until DNA and RNA isolation. The other set 
of samples was directed for histopathological examina-
tion performed by an experienced pathologist. None of 
the patients received preoperative chemo- or radiotherapy. 
Informed consent was obtained from all participating 
individuals. The procedures of the study were approved 
by the Local Ethical Committee of Poznan´ University of 
Medical Sciences. Written consent was obtained from all 
participants.
Measurement of overall and disease-free survival
Follow-up data were available for 88 patients, who were 
observed from 2009/08/01 until death or 2014/25/05, 
whichever came first. Disease-free survival (DFS) is 
defined as the time elapsed from surgery to the first occur-
rence of any of the following events: recurrence or distant 
metastasis of CRC or the development of a second non-
colorectal malignancy. The diagnosis of recurrence and 
metastasis was evaluated with a variety of methods, includ-
ing computed tomography, ultrasonography, position emis-
sion tomography, cytologic analysis or biopsy. Overall sur-
vival (OS) is defined as the time elapsed from surgery to 
the death of the CRC patient. Death of patients was verified 
by public records and family reports. The DFS and OS sta-
tuses were ascertained by a physician blinded to the TET 
mRNA levels.
Table 1  Clinicopathological characteristics of patients with colorec-
tal cancer
Features No. of patients
Total no. of patients 113
Gender (female/male) 47/66




 Proximal colon (cecum to transverse) 39
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DNA isolation and bisulfite modification
Genomic DNA from the tissues of patients with CRC was 
isolated using the DNA Mammalian Genomic Purification 
Kit purchased from Sigma-Aldrich Co. (St. Louis, MO). 
Then, 500 ng of genomic DNA was subjected to bisulfite 
conversion of cytosine to uracil, according to the EZ DNA 
Methylation Kit™ procedure from Zymo Research Corpo-
ration (Orange, CA). The positions of the CpG islands and 
transcription factor-binding sites located in the TET1, TET2 
and TET3 promoters were determined by online programs 
(CpGPlot/CpGReport/Isochore; Searcher; Site).
DNA methylation evaluation by bisulfite sequencing
The DNA fragments containing CpG dinucleotides located 
in the promoter region of the TET1, TET2 and TET3 
genes were amplified by the primer pairs complementary 
to the bisulfite-DNA modified sequences (Supplemen-
tary Table 1). PCR amplification was performed by Fast-
Start Taq DNA Polymerase from Roche Diagnostic GmbH 
(Mannheim, Germany). The PCR products were purified 
using Agarose Gel DNA Extraction Kit, Roche Diagnos-
tic GmbH (Mannheim, Germany) with subsequent cloning 
into pGEM-T Easy Vector System I, Promega (Madison, 
WI) and transformation into TOPO10 E. coli strain cells. 
The plasmid DNA isolated from five positive bacterial 
clones was used for commercial sequencing of the cloned 
fragment of DNA. The results of bisulfite sequencing were 
assessed and presented using BiQ analyzer software and 
bisulfite sequencing data presentation and compilation 
(BDPC) web server, respectively (Bock et al. 2005; Rohde 
et al. 2008).
DNA methylation assessment by high-resolution melting 
(HRM) analysis
The methylation levels of DNA fragments located within 
the CpG islands of the TET1, TET2 and TET3 genes were 
determined by real-time PCR amplification of bisulfite-
treated DNA, followed by HRM profile analysis by Light 
Cycler®480 or LightCycler®96 Real-Time PCR Sys-
tem, Roche Diagnostics GmbH (Mannheim, Germany). 
For PCR amplification, 1 μl of either the bisulfite-treated 
DNA from patients or standards, together with primers 
(Supplementary Table 1), was added to 19 μl of 5 X Hot 
FIREPol EvaGreen HRM Mix, Solis BioDyne Co. (Tartu, 
Estonia). Standardized solutions with a given DNA meth-
ylation percentage were prepared by mixing methylated 
and non-methylated bisulfite-treated DNA from the Human 
Methylated/Non-methylated DNA Set, Zymo Research 
Corp. (Orange, CA) in different ratios. To determine the 
percentage of methylation, the HRM profiles of patients’ 
DNA PCR products were compared with HRM profiles of 
standard DNA PCR products (Rawluszko et al. 2011; Woj-
dacz and Dobrovic 2007). HRM methylation analysis was 
performed using the Light Cycler®480 or LightCycler®96 
Gene Scanning software, Roche Diagnostics GmbH (Man-
nheim, Germany). Each PCR amplification and HRM 
profile analysis was performed in triplicate. The methyla-
tion status for each patient was presented as a percentage 
of methylation in amplified fragments located in the CpG 
islands of TET1, TET2 and TET3.
RNA isolation, reverse transcription and real-time 
quantitative polymerase chain reaction (RQ-PCR) analysis
Total RNA from the tissues of patients with CRC was iso-
lated according to the method of Chomczyn´ski and Sacchi 
(1987). The RNA samples were quantified and reverse-
transcribed into cDNA. RQ-PCR was carried out in the 
Light Cycler®480 Real-Time PCR System, Roche Diag-
nostics GmbH (Mannheim, Germany) using SYBR® Green 
as the detection dye. The target cDNA was quantified by 
the relative quantification method using a calibrator for the 
primary tissues. The calibrator was prepared as a cDNA 
mix from all of the patients’ samples, and successive dilu-
tions were used to create a standard curve as described in 
Relative Quantification Manual, Roche Diagnostics GmbH 
(Mannheim, Germany). For amplification, 1 μl of (total 
20 μl) cDNA solution was added to 9 μl of IQ™ SYBR® 
Fig. 1  TET1, TET2 and TET3 transcript levels in primary cancerous 
and histopathologically unchanged tissues from patients with CRC. 
The cancerous (C) and histopathologically unchanged tissues (HU) 
from 113 patients with CRC were used for RNA isolation. Total RNA 
was reverse-transcribed, and cDNAs were investigated by RQ-PCR 
relative quantification analysis. The TET1, TET2 and TET3 mRNA 
levels were corrected by the geometric mean of PBGD and hMRPL19 
cDNA levels. The amounts of TET1, TET2 and TET3 mRNA were 
expressed as the decimal logarithm of multiples of these cDNA cop-
ies in the calibrator
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Table 2  TET1 (A), TET2 
(B) and TET3 (C) transcript 
levels in primary cancerous and 
histopathologically unchanged 
tissue samples from patient with 
CRC
Primary cancerous tissue Histopathologically unchanged tissue pa
Mean (range)
A. TET1
2.79 (1.84–3.81) 3.13 (1.62–3.88) 0.000001
Age (years)
 <60 2.78 (2.36–3.70) 3.09 (1.62–3.54) 0.0036
 >60 2.78 (1.84–3.81) 3.14 (2.23–3.89) 0.000001
Gender
 Female 2.79 (1.84–3.35) 3.16 (2.23–3.89) 0.000001
 Male 2.77 (2.10–3.81) 3.11 (1.62–3.78) 0.000001
Localization
 Proximal colon 2.69 (1.84–3.81) 3.16 (1.62–3.88) 0.000001
 Distal colon 2.77 (2.35–3.29) 3.16 (2.85–3.78) 0.000016
 Rectum 2.85 (2.20–3.70) 3.09 (2.23–3.62) 0.000043
Histological grade
 G1 2.83 (2.57–3.03) 3.18 (2.91–3.43) 0.022
 G2 2.76 (1.84–3.70) 3.13 (2.23–3.78) 0.000001
 G3 2.81 (2.10–3.81) 3.11 (1.62–3.88) 0.00084
TNM classification
 I 2.77 (2.54–3.04) 3.15 (2.77–3.78) 0.00023
 IIA 2.68 (1.84–3.70) 3.13 (1.62–3.76) 0.000004
 IIC 2.70 (2.10–3.17) 3.25 (3.07–3.60) 0.21
 IIIA 2.76 (2.58–2.94) 3.18 (2.84–3.27) 0.92
 IIIB 2.84 (2.14–3.81) 3.07 (2.23–3.88) 0.0039
 IIIC 2.84 (2.46–3.28) 3.21 (2.95–3.54) 0.00028
B. TET2
2.76 (2.18–3.63) 3.03 (1.28–3.63) 0.000001
Age (years)
 <60 2.76 (2.30–3.18) 2.98 (1.28–3.26) 0.0057
 >60 2.76 (2.18–3.63) 3.03 (1.43–3.63) 0.000001
Gender
 Female 2.75 (2.34–3.23) 3.01 (2.71–3.40) 0.000001
 Male 2.76 (2.18–3.63) 3.03 (1.28–3.63) 0.000001
Localization
 Proximal colon 2.71 (2.28–3.58) 3.04 (1.28–3.42) 0.000001
 Distal colon 2.68 (2.38–3.07) 3.05 (2.78–3.48) 0.000014
 Rectum 2.79 (2.18–3.63) 2.97 (1.43–3.63) 0.00002
Histological grade
 G1 2.69 (2.22–3.06) 3.02 (2.72–3.26) 0.21
 G2 2.74 (2.18–3.23) 3.01 (1.43–3.63) 0.000001
 G3 2.79 (2.30–3.63) 3.04 (1.28–3.39) 0.00025
TNM classification
 I 2.73 (2.46–3.00) 2.98 (2.72–3.63) 0.0035
 IIA 2.64 (2.30–3.23) 3.04 (1.28–3.42) 0.000002
 IIC 3.00 (2.66–3.07) 3.07 (2.92–3.11) 0.38
 IIIA 2.79 (2.70–2.87) 2.91 (2.81–3.00) 0.69
 IIIB 2.79 (2.18–3.63) 2.97 (1.43–3.26) 0.00062
 IIIC 2.76 (2.44–3.03) 3.03 (2.76–3.13) 0.0017
C. TET3
2.93 (0.96–4.08) 3.03 (1.12–3.77) 0.00031
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Green Supermix, Bio-Rad Laboratories Inc. (Hercules, 
CA) with primers (Supplementary Table 1). To prevent the 
amplification of sequences from genomic DNA contami-
nation, primers and/or amplicons were designed at exon/
exon boundaries and covered all gene splice variants. The 
quantity of TET1, TET2 and TET3 transcripts in each sam-
ple was standardized by the geometric mean of two inter-
nal controls: porphobilinogen deaminase (PBGD) and 
human mitochondrial ribosomal protein L19 (hMRPL19) 
(Supplementary Table 1). The selection of internal con-
trol genes was performed as previously described (Raw-
luszko-Wieczorek et al. 2014). The TET1, TET2 and TET3 
transcript levels in the patients’ tissues were expressed as 
a multiplicity of the cDNA concentrations in the calibra-
tor. A few samples, in which the quantity of isolated RNA 
was insufficient to prepare high-quality RQ-PCR products, 
were excluded from further analysis. Hence, the number of 
patients in the subgroups of survival analysis may vary by 
±4 samples.
Statistical analysis
The normality of the observed patient data distribution was 
assessed using the Shapiro–Wilk test, and the median val-
ues were compared using the U Mann–Whitney test. Sur-
vival curves were plotted using the Kaplan–Meier method, 
and survival differences were determined using the log rank 
test. The multivariable Cox proportional hazard model was 
used to estimate the adjusted hazard ratio (HR). Statistical 
analysis was performed with the STATISTICA 10.0 soft-
ware, and p < 0.05 was considered statistically significant.
Results
mRNA levels of TET family members are 
significantly decreased in cancerous tissues compared 
with histopathologically unchanged tissues from patients 
with CRC
We used RQ-PCR to compare TET1, TET2 and TET3 
transcript levels in cancerous and histopathologically 
unchanged tissues in 113 patients with CRC. We found sig-
nificantly lower levels of TET1, TET2 and TET3 mRNA 
levels (p = 0.000011; p = 0.000001; p = 0.00031, respec-
tively) in cancerous tissues than in histopathologically 
unchanged tissues (Fig. 1). The lower levels of TET1 and 
TET2 mRNA levels in cancerous tissues were observed 
across different age groups, genders, CRC localization, 
histological grades and TNM classification (Table 2A, B). 
Differences in the IIC and IIIA TNM classes did not reach 
statistically significant results for all the TETs, most likely 
Table 2  continued Primary cancerous tissue Histopathologically unchanged tissue pa
Mean (range)
Age (years)
 <60 2.96 (2.17–3.99) 3.02 (1.65–3.66) 0.13
 >60 2.91 (0.95–4.08) 3.03 (1.12–3.77) 0.0013
Gender
 Female 2.92 (2.22–3.99) 3.04 (2.49–3.77) 0.025
 Male 2.92 (0.96–4.08) 3.01 (1.12–3.59) 0.0065
Localization
 Proximal colon 2.90 (2.17–4.08) 3.07 (1.65–3.77) 0.00034
 Distal colon 2.88 (2.22–3.28) 2.95 (2.56–3.66) 0.26
 Rectum 2.94 (0.96–3.99) 2.97 (1.12–3.46) 0.36
Histological grade
 G1 3.06 (2.91–3.19) 3.08 (2.78–3.46) 0.99
 G2 2.90 (0.96–3.45) 3.02 (1.99–3.77) 0.00053
 G3 2.94 (2.17–4.08) 3.03 (1.12–3.59) 0.078
TNM classification
 I 2.94 (2.22–3.28) 3.12 (1.99–3.59) 0.064
 IIA 2.94 (2.17–3.99) 3.02 (1.65–3.77) 0.069
 IIC 2.84 (2.42–3.23) 3.16 (2.56–3.26) 0.66
 IIIA 2.89 (2.84–2.94) 2.97 (2.88–3.06) 0.70
 IIIB 2.89 (0.96–4.08) 2.98 (1.12–3.49) 0.029
 IIIC 3.00 (2.84–3.37) 3.03 (2.82–3.66) 0.95
The TET1, TET2 and 
TET3 transcript levels were 
standardized by the geometric 
mean of PBGD and hMRPL19 
cDNA and expressed as decimal 
logarithm of multiples of these 
cDNA copies in calibrator
a U Mann–Whitney test
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due to the small number of patients in these subgroups. 
However, age and localization-related expression was 
observed for the TET3 transcript. Significantly lower TET3 
mRNA levels in the cancerous tissues was observed in the 
groups of patients above 60 years of age, and in tumors 
localized in the proximal colon (Table 2C).
DNA methylation level of promoter region of TET genes
To compare DNA methylation levels in the TET1, TET2 
and TET3 promoter regions between DNA samples from 
the cancerous and histopathologically unchanged tissues, 
we performed bisulfite DNA sequencing followed by 
HRM analysis. Bisulfite sequencing was used for evalua-
tion of DNA methylation in large regions of CpG islands 
in randomly selected patients. We detected a similar pattern 
of DNA methylation within all individual clones of each 
patient. We undetected DNA methylation of TET2 (chr4: 
106,067,501–106,068,077) and TET3 (chr2: 74,211,418–
74,211,829) promoter regions using bisulfite sequencing 
in selected patients (Fig. 2b, c). In keeping with bisulfite 
sequencing data, we have not observed DNA methylation 
within TET2 (chr4: 106 067,537–106,067 735) and TET3 
(ch42: 74,211,418–74,211 584) promoter regions in 113 
patients with CRC (Fig. 3b, c). Although HRM analysis 
revealed no DNA methylation in TET1 promoter region 
(chr10: 70 320 271–70,320 457) of 101 samples, significant 
DNA hypermethylation in cancerous tissues, compared to 
histopathologically unchanged tissues, was observed in 12 
patients (Fig. 3a). The DNA hypermethylation of TET1-
selected region was also observed using bisulfite sequenc-
ing (Fig. 2a). Patients numbered P2–P4 are among group 
with detected DNA methylation in cancerous tissue using 
HRM analysis (Fig. 2a). Stratification of the patients with 
Fig. 2  DNA methylation assessment of TET1, TET2 and TET3 
gene regulatory region by bisulfite sequencing in tissue samples 
from patients with CRC. Primary cancerous and histopathologically 
unchanged tissues from the same patients with CRC (P1–P5) were 
used for genomic DNA isolation followed by bisulfite conversion of 
cytosine to uracil. The TET1, TET2 and TET3 regions containing 
47, 64 and 40 CpG dinucleotides, respectively, were then amplified 
by a pair of primers complementary to the bisulfite-DNA modified 
sequence. The PCR products were purified with subsequent clon-
ing into a plasmid vector. Plasmid DNA isolated from five positive 
bacterial clones was used for commercial sequencing. The results of 
bisulfite sequencing were assessed and presented using BiQ analyzer 
software and BDPC web server. Black, gray and white boxes repre-
sent methylated, unmethylated or undetermined CpG dinucleotide, 
respectively
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Fig. 3  DNA methylation 
assessment of TET1, TET2 
and TET3 gene regulatory 
region by HRM analysis in 
tissue samples from patients 
with CRC. Primary cancer-
ous and histopathologically 
unchanged tissues from the 
same patients with CRC 
were used for genomic DNA 
isolation followed by bisulfite 
conversion of cytosine to uracil. 
a–c Represent HRM profiles of 
standard and example of patient 
DNA PCR product for TET1, 
TET2 and TET3, respectively. 
Methylation percentage of 
DNA fragments within the 
CpG island was determined by 
real-time PCR amplification of 
bisulfite-treated standard and 
patient DNA, followed by com-
parison of their HRM profiles. 
DNA standards were prepared 
by mixing different ratios of 
methylated and non-methylated 
bisulfite-treated standard DNA. 
HRM methylation analysis 
was performed using Light 
Cycler®480 or LightCycler®96 
Gene Scanning software, Roche 
Diagnostics GmbH (Mannheim, 
Germany). Each PCR amplifica-
tion and HRM profile analysis 
was performed in triplicate
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increased DNA methylation in the TET1 promoter by gen-
der, age, localization, histological grade and TNM did not 
reveal any significant tendency (Table 3). Nonetheless, 
patients with DNA hypermethylation in the TET1 regula-
tory region of cancerous tissues have lower TET1 transcript 
levels (p = 0.074), compared to cancerous tissues with no 
DNA methylation changes in the same region (Fig. 4).
TET2 mRNA levels have prognostic potential in CRC 
patients’ overall and disease-free survival
To assess the effect of mRNA and DNA methylation levels 
of TET gene family members, we performed a retrospective 
analysis of 88 patients. The patients’ median survival was 38 
(range 4–59) months. The transcript levels of TET1, TET2 
and TET3 were divided into three groups: low, intermedi-
ate and high mRNA levels. The analysis of TET1 transcript 
levels in histopathologically unchanged tissues and TET2 in 
cancerous tissue did not reveal statistically significant results 
(Fig. 5a, c). However, compared to those with intermediate 
and high TET1 transcript levels, patients with low TET1 
mRNA levels in cancerous tissues trended toward favorable 
DFS outcomes (Fig. 5a). Although these results did not reach 
statistical significance, low TET1 mRNA levels in cancer-
ous tissue also correlated with increased patient OS, with 
a median survival of 41 months versus 36 and 33 months 
for intermediate and high TET1 mRNA levels, respectively 
(Fig. 5a). Moreover, follow-up data were available for eight 
out of 12 patients with DNA hypermethylation within CpG 
islands of the TET1 gene in cancerous tissues. Log rank 
test analysis did not reveal statistically significant results 
for the patients with DNA methylation (Fig. 5b). Further, 
Kaplan–Meier analysis revealed that the CRC patients with 
high TET2 mRNA level in histopathologically unchanged 
tissues had better overall and DFS outcomes (OS median: 
41 months; DFS median: 40 months) than those with low 
TET2 mRNA levels (OS median: 26.5 months; DFS median: 
28 months) (Fig. 5c). In the present study, analysis of TET3 
mRNA levels in histopathologically unchanged and cancer-
ous colorectal tissues revealed no significant correlation with 
the patients’ OS and DFS (Fig. 5d).
We performed multivariable analysis for TET2 mRNA 
levels in histopathologically unchanged tissues and for 
TET1 mRNA level in cancerous tissues. In Cox propor-
tional hazard regression analysis, the categorical variables 
introduced included age, gender, tumor localization and 
postoperative chemotherapy. In the current study, adjusted 
analysis did not reveal statistically significant results for 
TET1 mRNA levels in cancerous tissues (Table 4). How-
ever, multivariable analysis revealed that high TET2 mRNA 
levels in histopathologically unchanged tissues can be an 
independent prognostic factor for OS and DFS (Table 5).
Discussion
Identification of TET activity was a milestone in under-
standing the dynamic landscape of the epigenome. 
Table 3  Clinicopathological 
characteristics of CRC 
patients with TET1 DNA 
hypermethylation in cancerous 
tissue




Histological grade (G1/G2/G3) 2/7/3
TNM (I/IIA/IIC/IIIB) 3/5/1/3
Fig. 4  DNA methylation effect on TET1 mRNA levels in cancerous 
tissue. The primary cancerous tissues from 113 patients with CRC 
were used for RNA isolation. Total RNA was reverse-transcribed, and 
cDNAs were investigated by RQ-PCR relative quantification analy-
sis. The TET1 mRNA levels were corrected by the geometric mean 
of PBGD and hMRPL19 cDNA levels. The amount of TET1 mRNA 
was expressed as the decimal logarithm of multiples of cDNA copies 
in the calibrator
1387J Cancer Res Clin Oncol (2015) 141:1379–1392 
1 3
Although the precise role of TET in physiological pro-
cesses and diseases necessitates further elucidation, recent 
data point to a role of TETs in maintaining 5-hmC at 
genes susceptible to hypermethylation in cancer (Putiri 
et al. 2014). Several reports have also found a correla-
tion between reduced 5-hmC and poor patient prognosis 
in various cancers (Hsu et al. 2012; Lian et al. 2012; Liu 
et al. 2013; Orr et al. 2012). We have observed reduced 
TET1, TET2 and TET3 transcript levels in a cohort of 113 
CRC patients. These data support previous observations 
of lower levels of TET mRNA in other types of solid can-
cers: reduced TET1 expression had been found in the can-
cerous tissues of breast, prostate and hepatocellular car-
cinomas (Frycz et al. 2014; Liu et al. 2013; Muller et al. 
Fig. 5  The Kaplan–Meier survival analysis among patients with 
colorectal cancer according to the TET1 mRNA level (a), TET1 
DNA methylation (b), TET2 (c) and TET3 (d) mRNA level. Patients 
were subdivided into three groups: low, intermediate, and high for 
each TET1, TET2 and TET3 transcript levels in histopathologically 
unchanged and cancerous tissue or DNA methylation absent/present 
in TET1 promoter in cancerous tissue. p values for overall survival 
(OS) and disease-free survival (DFS) were determined with the log 
rank test and given only for significant results. n, number of patients
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2012); moreover, all three TET family members were 
downregulated at the mRNA level in breast cancer and 
melanoma (Hsu et al. 2012; Lian et al. 2012; Yang et al. 
2013). Interestingly, we also observed reduced TET3 
mRNA levels in the cancerous tissues from patients above 
60 years of age, and in tumors localized in the proxi-
mal colon. The proximal colon, distal colon and rectum 
develop from different embryological origins, as reflected 
by their vascular supplies, glucose metabolism and anti-
gen presentation (Distler and Holt 1997). Moreover, dur-
ing carcinogenesis, epigenetic changes mostly occur at 
the proximal site, whereas genetic background of tumor 
is characteristic for distal site and rectum (Jass 2007). 
To date, several publications have reported the sub-site-
specific expression of genes in CRC (Glebov et al. 2003; 
Papaxoinis et al. 2010; Rawluszko et al. 2011), supporting 
the differences we observed in the TET3 transcript levels 
in the proximal colon.
Furthermore, we investigated for the first time the 
prognostic importance of TET mRNA levels in CRC. Sur-
prisingly, we observed that the patients with low TET1 
mRNA levels in cancerous tissues trended toward favora-
ble outcomes. However, this tendency was not observed 
in multivariate analysis. In earlier studies, decreased 
TET1 mRNA levels in breast cancer were associated 
with increased invasiveness and metastasis in vitro and 
in vivo (Hsu et al. 2012). Our results in CRC need to 
be validated in large, multicenter studies with extended 
follow-ups and be verified through molecular analyses. 
However, we detected that high TET2 mRNA levels in 
histopathologically unchanged tissues may be related to 
favorable outcomes. To the best of our knowledge, this is 
the first report presenting such a result in a solid tumor. 
Previously, the significance of TET2 expression in car-
cinogenesis was studied particularly for lymphomas and 
leukemias. In TET2 knockout studies, decreases in 5-hmC 
levels stimulated the self-renewal of hematopoietic stem 
cells and their altered development toward the monocyte 
lineage (Ko et al. 2011; Moran-Crusio et al. 2011). More-
over, loss-of-function mutations in TET2, which impair 
its catalytic activity, are often observed in patients with 
chronic myelomonocytic leukemia (CMML), myelopro-
liferative neoplasms (MPN), myelodysplastic syndrome 
(MDS), as well as B cell and T cell lymphomas (Asmar 
et al. 2013; Couronne et al. 2012; Delhommeau et al. 
2009; Langemeijer et al. 2009).
Unlike TET2, loss-of-function mutations of TET1 
and TET3 are uncommon. Moreover, according to the 
COSMIC database, mutations in TET family mem-
bers in solid tumors are very rare (1–3 %). It should 
be noted that the TET1, TET2 and TET3 genes possess 
CpG islands in their promoter region. Thus, we inves-
tigated whether the reduction of the mRNAs in cancer-
ous tissues might stem from aberrant DNA methylation. 
However, in our study group, no DNA methylation was 
observed in histopathologically unchanged and cancer-
ous tissues at the TET2 and TET3 promoters. To date, 
TET2 promoter hypermethylation had been observed 
for low-grade diffuse gliomas, a subset of Ph-negative 
MPN and pediatric acute lymphoblastic leukemia (ALL) 
Fig. 5  continued
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(Chim et al. 2010; Musialik et al. 2014). The biological 
effects of TET2 hypermethylation, as reflected by lower 
5-hmC levels, had been observed in multiple sclerosis 
(Calabrese et al. 2014). On the contrary, DNA methyl-
ation in the TET2 promoter was not detected in MPN, 
MDS or CMML (Abdel-Wahab et al. 2009; Jankowska 
et al. 2009). To the best of our knowledge, DNA meth-
ylation within the TET3 promoter has not been reported, 
and our study presents its absence.
We found TET1 DNA hypermethylation in can-
cerous tissues from a small subset of CRC patients 
(n = 12/113). The Mann–Whitney test revealed that 
compared to the group without DNA methylation, the 
group with DNA methylation showed lower TET1 tran-
script levels in cancerous tissues. However, these find-
ings should be interpreted with caution, due to potential 
bias arising from the sample size. Although TET1 DNA 
methylation is a very interesting observation, the study 
should be extended to a larger group of patients to iden-
tify its biological significance and prognostic value. 
Consistent with our findings, other reports have also 
indicated the relevance of TET1 promoter DNA methyla-
tion in cancer. TET1 hypermethylation was observed in 
the ALL cell line SKW-3, and the cervical cancer cell 
Fig. 5  continued
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line in HeLa (Ciccarone et al. 2014). Moreover, TET1 
promoter was methylated in high-mobility group AT-
hook 2 (HMGA2; chromatin remodeling factor)-depleted 
breast cancer cells (Sun et al. 2013).
It is known that TET expression might be regulated post-
transcriptionally or posttranslationally (Delatte et al. 2014). 
Hence, the main limitation of our study is the lack of cor-
relation between TET protein levels and 5-hmC. Keep-
ing in mind the small amount of samples, we decided to 
investigate TET DNA methylation and mRNA levels in 
CRC because it had not been previously explored.
In conclusion, our study demonstrates that TET1, TET2, 
and TET3 transcript levels in cancerous tissues are reduced 
and provide the first evidence that TET2 mRNA in histo-
pathologically unchanged tissue from CRC patients may be 
an independent predictor of relapse and OS. Nevertheless, 
further large-scale, longitudinal studies are needed to con-
firm the clinical relevance of this observation. Moreover, 
Fig. 5  continued
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DNA methylation within the TET1 promoter region sug-
gests it may play a role in regulating TET1 gene expres-
sion. Nonetheless, in the context of CRC, this hypothesis 
still necessitates direct testing by additional in vitro and in 
vivo studies.
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